Shrinidh Joshi1, Yagna P R Jarajapu1. 1. Department of Pharmaceutical Sciences, College of Health Professions, North Dakota State University, Fargo, ND, USA.
Abstract
BACKGROUND AND PURPOSE: CD34+ haematopoietic stem/progenitor cells have revascularization potential and are now being tested for the treatment of ischaemic vascular diseases in clinical trials. We tested the hypothesis that mitochondrial depolarization stimulates the reparative functions of CD34+ cells. EXPERIMENTAL APPROACH: Peripheral blood was obtained from healthy individuals (n = 63), and mononuclear cells (MNCs) were separated. MNCs were enriched for lineage negative cells, followed by isolation of CD34+ cells. Vascular repair-relevant functions of CD34+ cells, proliferation and migration, were evaluated in the presence and absence of diazoxide. Mitochondrial membrane potential, ROS and NO levels were evaluated by flow cytometry by using JC-1, mitoSOX and DAF-FM respectively. KEY RESULTS: Diazoxide stimulated the proliferation and migration of CD34+ cells that were comparable to the responses induced by stromal-derived factor-1α (SDF) or VEGF. Effects of diazoxide were blocked by either 5-hydroxydecanoate (5HD), a selective mitochondrial ATP-sensitive potassium channel (mitoKATP ) inhibitor, or by L-NAME. Diazoxide induced mitochondrial depolarization, and NO and cGMP generation that were 5HD-sensitive. The generation of NO and cGMP by diazoxide was blocked by an endothelial NOS (eNOS)-selective inhibitor, NIO, but not by a neuronal (n)NOS-selective inhibitor, Nω -propyl-L-arginine (NPA). A Ca2+ chelator, BAPTA, Akt inhibitor, triciribine, or PI3K inhibitor, LY294002, inhibited the NO release induced by diazoxide. Phosphorylation of eNOS at Ser1177 and dephosphorylation at Thr495 were increased. Diazoxide-induced ROS generation and phosphorylation of eNOS at Ser1177 were reduced by NPA. CONCLUSION AND IMPLICATIONS: Diazoxide stimulates vascular repair-relevant functions of CD34+ cells via the mitoKATP -dependent release of NO and ROS. LINKED ARTICLES: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc.
BACKGROUND AND PURPOSE:CD34+ haematopoietic stem/progenitor cells have revascularization potential and are now being tested for the treatment of ischaemic vascular diseases in clinical trials. We tested the hypothesis that mitochondrial depolarization stimulates the reparative functions of CD34+ cells. EXPERIMENTAL APPROACH: Peripheral blood was obtained from healthy individuals (n = 63), and mononuclear cells (MNCs) were separated. MNCs were enriched for lineage negative cells, followed by isolation of CD34+ cells. Vascular repair-relevant functions of CD34+ cells, proliferation and migration, were evaluated in the presence and absence of diazoxide. Mitochondrial membrane potential, ROS and NO levels were evaluated by flow cytometry by using JC-1, mitoSOX and DAF-FM respectively. KEY RESULTS:Diazoxide stimulated the proliferation and migration of CD34+ cells that were comparable to the responses induced by stromal-derived factor-1α (SDF) or VEGF. Effects of diazoxide were blocked by either 5-hydroxydecanoate (5HD), a selective mitochondrial ATP-sensitive potassium channel (mitoKATP ) inhibitor, or by L-NAME. Diazoxide induced mitochondrial depolarization, and NO and cGMP generation that were 5HD-sensitive. The generation of NO and cGMP by diazoxide was blocked by an endothelial NOS (eNOS)-selective inhibitor, NIO, but not by a neuronal (n)NOS-selective inhibitor, Nω -propyl-L-arginine (NPA). A Ca2+ chelator, BAPTA, Akt inhibitor, triciribine, or PI3K inhibitor, LY294002, inhibited the NO release induced by diazoxide. Phosphorylation of eNOS at Ser1177 and dephosphorylation at Thr495 were increased. Diazoxide-induced ROS generation and phosphorylation of eNOS at Ser1177 were reduced by NPA. CONCLUSION AND IMPLICATIONS: Diazoxide stimulates vascular repair-relevant functions of CD34+ cells via the mitoKATP -dependent release of NO and ROS. LINKED ARTICLES: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc.
Authors: Anastasia Andrukhiv; Alexandre D Costa; Ian C West; Keith D Garlid Journal: Am J Physiol Heart Circ Physiol Date: 2006-06-23 Impact factor: 4.733
Authors: Charlie R Mantel; Heather A O'Leary; Brahmananda R Chitteti; XinXin Huang; Scott Cooper; Giao Hangoc; Nickolay Brustovetsky; Edward F Srour; Man Ryul Lee; Steven Messina-Graham; David M Haas; Nadia Falah; Reuben Kapur; Louis M Pelus; Nabeel Bardeesy; Julien Fitamant; Mircea Ivan; Kye-Seong Kim; Hal E Broxmeyer Journal: Cell Date: 2015-06-11 Impact factor: 41.582
Authors: M Sattler; S Verma; C H Byrne; G Shrikhande; T Winkler; P A Algate; L R Rohrschneider; J D Griffin Journal: Mol Cell Biol Date: 1999-11 Impact factor: 4.272
Authors: Jennifer L Kielczewski; Yagna P R Jarajapu; Evan L McFarland; Jun Cai; Aqeela Afzal; Sergio Li Calzi; Kyung Hee Chang; Todd Lydic; Lynn C Shaw; Julia Busik; Jeffrey Hughes; Arturo J Cardounel; Kenneth Wilson; Timothy J Lyons; Michael E Boulton; Robert N Mames; Tailoi Chan-Ling; Maria B Grant Journal: Circ Res Date: 2009-09-17 Impact factor: 17.367
Authors: Prasad V G Katakam; Ferenc Domoki; James A Snipes; Anna R Busija; Yagna P R Jarajapu; David W Busija Journal: Am J Physiol Regul Integr Comp Physiol Date: 2008-11-12 Impact factor: 3.619
Authors: Jesmin Jahan; Ildamaris Monte de Oca; Brian Meissner; Shrinidh Joshi; Ahmad Maghrabi; Julio Quiroz-Olvera; Chrisitne Lopez-Yang; Stephen H Bartelmez; Charles Garcia; Yagna P Jarajapu Journal: Eur J Pharmacol Date: 2022-02-23 Impact factor: 4.432